Investors and analysts reacted immediately to Novo's revelation. The price of Novo's common stock declined dramatically. From a closing market price of $103.44 per share on December 19, 2024, Novo's ...

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Ken Fisher is the founder and executive chairman of Fisher Asset Management, a renowned investment and financial analysis ...

An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use of “affordable” compounded weight loss drugs.

Denmark’s Novo Nordisk (NOV: N) saw its shares rise as much as 13% to ... data analyses and commentary from our global network of life sciences reporters. Receive The Pharma Letter daily news bulletin ...

Both Novo Nordisk’s Ozempic (semaglutide ... suggesting fatty liver disease as one potential example. The potential for lifesaving benefits would justify expanding access, said Elizabeth ...

USA-based biotech IMMvention Therapeutix yesterday revealed it has entered into a strategic collaboration and license agreement with Novo Nordisk (NOV ... Receive The Pharma Letter daily news bulletin ...

Outgoing presidents traditionally leave a letter for the incoming president. Former President Joe Biden wished President Donald Trump "all the best for the next four years" in the letter he left ...

On Tuesday, BofA Securities expressed continued confidence in Novo Nordisk (NOVOB:DC) (NYSE: NYSE:NVO), maintaining a Buy rating and a price target of DKK1,075.00. The endorsement comes amidst ...

Medicare added Novo Nordisk's Ozempic, Wegovy, and Rybelsus to its 2027 drug price negotiations list. This move could force Novo Nordisk to slash the costs of its top drugs. The company should ...